COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
European Journal of Cancer Dec 04, 2017
Crabb SJ, et al. - In view of the efficacy of aspirin in minimising gentamicin-induced ototoxicity, researchers here tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy. They observed no protective effect of aspirin against cisplatin-related ototoxicity. Thereby suggesting distinct ototoxic mechanisms of cisplatin and gentamicin, or cisplatin-induced ototoxicity may be refractory to the aspirin regimen used here.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries